Disclosure Of First-Time Adoption [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166138

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	39,069 EUR	80,761 EUR	476,000 EUR	—	121,513 EUR	140,000 EUR	4,460 EUR	2,162 EUR	53,909 EUR	—	1,136 EUR	140,000 EUR	121,513 EUR	476,000 EUR	476,000 EUR	1,622 EUR	1,136 EUR	—	—	4,460 EUR	4,460 EUR	121,513 EUR	1,622 EUR	65,381 EUR	64,246 EUR	140,000 EUR	55,045 EUR	54,805 EUR	476,000 EUR	48,056 EUR	3,827 EUR	103,693 EUR	2,391 EUR	129,000 EUR
Comprehensive income	15,380 EUR	—	—	—	15,380 EUR	—	—	—	—	—	11,906 EUR	—	—	—	—	—	—	—	10,770 EUR	10,770 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit (loss)	15,380 EUR	—	—	—	—	—	—	—	—	—	11,906 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—